Drugs

Carisoprodol

Pharmacogenomic Information
  

DrugTherapeutic Area*
Biomarker†
Referenced
Subgroup
Labeling Sections
CarisoprodolRheumatologyCYP2C19CYP2C19 poor
metabolizers
Use in Specific Populations, Clinical Pharmacology
 

 

* Therapeutic areas do not necessarily reflect the CDER review division.

 
† Standard nomenclature is used for genes as per the Human Genome Organization symbol, cytogenetic abnormalities as per the International System for Human Cytogenetic Nomenclature, or other conventions.

 

back to Pharmacogenomic Biomarkers in Drug Labeling

Page Last Updated: 03/02/2015
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.